Role of BMI and hormone therapy in melanoma risk: a case–control study
- 301 Downloads
Currently, the association between body mass index (BMI) and hormone therapies and Cutaneous Melanoma (CM) development is strongly debated. This study was carried out to assess the association between BMI, hormone therapies, and CM risk.
The present study is a hospital-based case–control study with 605 consecutive CM patients and 592 controls treated for non-neoplastic conditions at the Department of Dermatology in Florence. The associations of melanoma risk with BMI and hormone therapies were assessed performing unconditional logistic regression to estimate odds ratios (OR) and their 95% confidence intervals, adjusting for potential confounders.
We found a significant interaction of BMI with age (P < 0.0001): being overweight significantly increased CM risk among individuals less than 50 years old (OR = 1.85 with 95% CI 1.14–2.94), whereas the association was not significant for individuals over 50 years old (OR = 1.15 with 95% CI 0.77–1.71). For oestrogen therapy, women taking oral contraceptives (OCs)/hormone replacement therapy (HRT) showed a lower CM risk than men (OR = 0.63, 95% CI 0.44–0.89), with risk estimates significantly lower (P < 0.0001) than in non OCs/HRT users, which had an increased risk compared to men (OR = 1.81, 95% CI 1.29–2.53).
Being overweight was significantly associated with CM risk, and this relationship was highly age-conditioned; the second finding was the protective effect of oestrogen therapies for women. Both findings may have a significant impact on melanoma prevention, as the prevalence of obesity and hormone therapy use is increasing worldwide.
KeywordsCutaneous melanoma Body mass index Overweight status Hormone therapies Age
Non-melanoma skin cancer
Hormone replacement therapy
Body mass index
Compliance with ethical standards
Conflict of interest
Vincenzo De Giorgi declares that he has no conflict of interest. Alessia Gori declares that she has no conflict of interest. Imma Savarese declares that she has no conflict of interest. Antonietta D’Errico declares that she has no conflict of interest. Federica Scarfi declares that she has no conflict of interest. Federica Papi declares that she has no conflict of interest. Vincenza Maio declares that she has no conflict of interest. Piero Covarelli declares that he has no conflict of interest. Daniela Massi declares that she has no conflict of interest. Sara Gandini declares that she has no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- Amjadi F, Javanmard SH, Zarkesh-Esfahani H, Khazaei M, Narimani M (2011) Leptin promotes melanoma tumor growth in mice related to increasing circulating endothelial progenitor cells numbers and plasma NO production. J Exp Clin Cancer Res 30:21. doi: 10.1186/1756-9966-30-21.CrossRefPubMedPubMedCentralGoogle Scholar
- Gallus S, Naldi L, Martin L, Martinelli M, La Vecchia C, Oncology Study Group of the Italian group for Epidemiologic Research in Dermatology (GISED) (2006) Anthropometric measures and risk of cutaneous malignant melanoma: a case-control study from Italy. Melanoma Res 16(1):83–87CrossRefPubMedGoogle Scholar
- Karagas MR, Stukel TA, Dykes J, Miglionico J, Greene MA, Carey M, Armstrong B, Elwood JM, Gallagher RP, Green A, Holly EA, Kirkpatrick CS et al. (2002) A pooled analysis of 10 case-control studies of melanoma and oral contraceptive use. Br J Cancer 86(7):1085–1092.CrossRefPubMedPubMedCentralGoogle Scholar
- Olsen CM, Zens MS, Green AC, Stukel TA, Holman CD, Mack T, Elwood JM, Holly EA, Sacerdote C, Gallagher R, Swerdlow AJ, Armstrong BK et al. (2011) Biologic markers of sun exposure and melanoma risk in women: pooled case-control analysis. Int J Cancer 129(3):713–723. doi: 10.1002/ijc.25691.CrossRefPubMedGoogle Scholar
- Randerson-Moor JA, Taylor JC, Elliott F, Chang YM, Beswick S, Kukalizch K, Affleck P, Leake S, Haynes S, Karpavicius B, Marsden J, Gerry E et al (2009) Vitamin D receptor gene polymorphisms, serum 25-hydroxyvitamin D levels, and melanoma: UK case-control comparisons and a meta-analysis of published VDR data. Eur J Cancer 45(18):3271–3281CrossRefPubMedPubMedCentralGoogle Scholar
- Tang JY, Henderson MT, Hernandez-Boussard T, Kubo J, Desai M, Sims ST, Aroda V, Thomas F, McTiernan A, Stefanick ML (2013) Lower skin cancer risk in women with higher body mass index: the women’s health initiative observational study. Cancer Epidemiol Biomark Prev 22(12):2482–2485CrossRefGoogle Scholar
- Taylor AW, Dal Grande E, Gill TK, Chittleborough CR, Wilson DH, Adams RJ, Grant JF, Phillips P, Appleton S, Ruffin RE (2006) How valid are self-reported height and weight? A comparison between CATI self-report and clinic measurements using a large cohort study. Aust N Z J Public Health 30(3):238–246CrossRefPubMedGoogle Scholar